Preeclampsia
Conditions
Brief summary
Preeclampsia is a frequent pathology. His etiology is doubtful. Targets : The study target is to identify a risk of preeclampsia group obtained with transcriptom analysis from circulating peripheric cells. Design: Multidisciplinary study (Gynaecology-Obstetric, Immunology, North CIC). The study of the transcriptional history of peripheral blood cells of 2patients groups: * A patient group with a preeclampsia before 34 SA * A patient group with a normal pregnancy paired on main confusion factors. Blood sampling will be collected at the diagnosis and 8 weeks after delivery. Results and perspectives * Obtain a transcriptionnal signature of preeclampsia * To identify new mechanism of the disease * Identification of a specific transcriptom analysis with the comparison after delivery For long-term, the target is to identify risk patient in order to conduct easily preventive clinical trials in preeclamsia (primary prevention) and to consider a specific follow-up for risk patients.
Interventions
OTHERsamples blood
OTHERbiopsy placentaire
Sponsors
Assistance Publique Hopitaux De Marseille
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
No
Inclusion criteria
* A prééclampsie (blood pressure superior to 140 mmHg and to 90 mmHg) and at least a cross of protein in the strip and/or more of 300mg / 24h after 20 LIMITED COMPANIES and before 34 limited companies. * An informed consent signed by the patient will necessarily have to be obtained. * Woman having been taken care during the pregnancy or at the time of the childbirth(delivery) by one of the participating teams to the current project. * Caucasian Patient * Wait primigeste and nullipare
Exclusion criteria
* Major Patient protected by the law. * Patient deprived of freedom for administrative or judicial reasons. * Patient not benefiting from a national insurance scheme. * Refusal of the patient to participate in the study. * Not Caucasian Patient * Multipare Wait * Multiple Pregnancy * Existence of foetal deformation explaining a delay of growth or a foetal death in utero. * Age 18 years and \> 40 years. * Absence of written consent or impossibility to receive the written consent (language or understanding).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| predictive markers of preeclampsia | 36 months | blood samples |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| analysis of placental transcriptional profile. | 36 months | biopsie placentaire |
Countries
France
Contacts
Primary Contactflorence bretelle
Outcome results
None listed